<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402350</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-003-101</org_study_id>
    <secondary_id>8 May 2006</secondary_id>
    <nct_id>NCT00402350</nct_id>
  </id_info>
  <brief_title>Staccato Fentanyl Single and Multidose PK</brief_title>
  <official_title>Safety, Tolerability, and Pharmacokinetics of Staccato® Fentanyl for Inhalation in Normal, Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase I clinical trial in approximately 50 healthy volunteers will be conducted at a&#xD;
      single clinical center in two stages. Stage 1 is an open-label, cross-over comparison of a&#xD;
      single dose of Staccato Fentanyl and an equivalent dose of intravenous (IV) fentanyl. Stage 2&#xD;
      is a randomized, doubleblind, placebo-controlled dose escalation of Staccato Fentanyl,&#xD;
      evaluating multiple doses of fentanyl. The three primary aims of the Phase I clinical trial&#xD;
      are to evaluate the pharmacokinetics (PK) and absolute bioavailability for Fentanyl, compare&#xD;
      the Staccato Fentanyl PK profile to the IV fentanyl PK profile, and examine the tolerability&#xD;
      and safety of Staccato Fentanyl in a non-opioid-tolerant, healthy volunteer population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the plasma PK profile of fentanyl following single and multiple Staccato Fentanyl doses</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess Staccato Fentanyl absolute bioavailability and dose proportionality</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Staccato Fentanyl</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Breakthrough Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects (2) from each of the 4 dose escalation arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mcg IV and Inhaled Crossover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose crossover (IV vs Inhaled)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled fentanyl 25 mcg x 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato fentanyl, 25 mcg x 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled fentanyl 25 mcg x 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato fentanyl, 25 mcg x 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled fentanyl 25 mcg x 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato fentanyl, 25 mcg x 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled fentanyl 25 mcg x 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato fentanyl, 25 mcg x 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Placebo</intervention_name>
    <description>Inhaled Staccato Placebo, same number of doses as active comparator in that arm</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Fentanyl 25 mcg</intervention_name>
    <description>Inhaled Staccato Fentanyl, 25 mcg x 1 dose</description>
    <arm_group_label>25 mcg IV and Inhaled Crossover</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Fentanyl 25 mcg</intervention_name>
    <description>Intravenous Fentanyl 25 mcg, single dose</description>
    <arm_group_label>25 mcg IV and Inhaled Crossover</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Fentanyl 25 mcg x 2</intervention_name>
    <description>Inhaled Staccato Fentanyl, 25 mcg x 2 doses</description>
    <arm_group_label>Inhaled fentanyl 25 mcg x 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Fentanyl 25 mcg x 4</intervention_name>
    <description>Inhaled Staccato Fentanyl, 25 mcg x 4 doses</description>
    <arm_group_label>Inhaled fentanyl 25 mcg x 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Fentanyl 25 mcg x 6</intervention_name>
    <description>Inhaled Staccato Fentanyl, 25 mcg x 6 doses</description>
    <arm_group_label>Inhaled fentanyl 25 mcg x 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Fentanyl 25 mcg x 12</intervention_name>
    <description>Inhaled Staccato Fentanyl, 25 mcg x 12 doses</description>
    <arm_group_label>Inhaled fentanyl 25 mcg x 12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects between the ages of 18 to 55 years, inclusive.&#xD;
&#xD;
          2. Subjects with a body mass index (BMI) ≥ 21 and ≤ 30.&#xD;
&#xD;
          3. Female subjects who are not pregnant, or are surgically sterile or 2 years&#xD;
             postmenopausal. If of childbearing potential, she must be using a medically-accepted&#xD;
             method of birth control and agree to continue use of this method for at least 30 days&#xD;
             after the study (i.e., barrier method with spermicide, steroidal contraceptive [oral,&#xD;
             transdermal, and implanted, including Depo-Provera; contraceptives must be used in&#xD;
             conjunction with a barrier method], or intrauterine device).&#xD;
&#xD;
          4. Subjects who speak, read, and understand English and are willing and able to provide&#xD;
             written informed consent on an IRB-approved form prior to the initiation of any study&#xD;
             procedures.&#xD;
&#xD;
          5. Subjects who are willing and able to be confined to the Clinical Research Unit (CRU)&#xD;
             for approximately 10 hours and comply with the study schedule and study requirements.&#xD;
&#xD;
          6. Subjects who are in good general health as determined by a complete medical history,&#xD;
             physical examination, 12-lead ECG, spirometry, blood chemistry profile, hematology,&#xD;
             and urinalysis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who regularly consume large amounts of xanthine-containing substances (i.e.,&#xD;
             more than 5 cups of coffee or equivalent amounts of xanthine-containing substances per&#xD;
             day).&#xD;
&#xD;
          2. Subjects who have taken prescription or nonprescription medication (with the exception&#xD;
             of vitamins, acetaminophen, and steroidal contraceptives for women of child-bearing&#xD;
             potential if medically necessary) within 5 days of Visits 2 or 3.&#xD;
&#xD;
          3. Subjects who have had an acute illness within 5 days of either Visit 2 or 3.&#xD;
&#xD;
          4. Subjects who have received an investigational drug within 30 days (or within 5 half&#xD;
             lives of the investigational drug) prior to Visit 2 or 3.&#xD;
&#xD;
          5. Subjects who have smoked tobacco within the last year.&#xD;
&#xD;
          6. Subjects who have a history within the past 2 years of drug or alcohol dependence or&#xD;
             abuse as defined by DSM-4.&#xD;
&#xD;
          7. Subjects with a history of HIV positivity.&#xD;
&#xD;
          8. Subjects with a history of allergy or intolerance to opioids.&#xD;
&#xD;
          9. Subjects who test positive for alcohol or have a positive urine drug screen at any&#xD;
             study visit.&#xD;
&#xD;
         10. Subjects who have hypotension (systolic blood pressure ≤90 mmHg, diastolic blood&#xD;
             pressure ≤50 mmHg), or hypertension (systolic blood pressure ≥140 mmHg, diastolic&#xD;
             blood pressure ≥90 mmHg).&#xD;
&#xD;
         11. Subjects who have a clinically significant ECG abnormality (beyond 1st degree heart&#xD;
             block).&#xD;
&#xD;
         12. Subjects with a history of unstable angina, syncope, coronary artery disease,&#xD;
             myocardial infarction, congestive heart failure (CHF), stroke, transient ischemic&#xD;
             attack (TIA), or a significant neurological disorder.&#xD;
&#xD;
         13. Subjects who have a history of pulmonary disease (asthma, bronchitis, bronchospasm,&#xD;
             emphysema).&#xD;
&#xD;
         14. Subjects who have an FEV1 less than 80% of predicted values on spirometry assessments&#xD;
             at Visit 1.&#xD;
&#xD;
         15. Female subjects who are breastfeeding or have a positive pregnancy test at any visit&#xD;
             must be excluded.&#xD;
&#xD;
         16. Subjects who have any other disease or condition, by history, physical examination, or&#xD;
             laboratory abnormalities that in the investigator's opinion, would present undue risk&#xD;
             to the subject, or may confound the interpretation of study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tong J Gan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Macleod DB, Habib AS, Ikeda K, Spyker DA, Cassella JV, Ho KY, Gan TJ. Inhaled fentanyl aerosol in healthy volunteers: pharmacokinetics and pharmacodynamics. Anesth Analg. 2012 Nov;115(5):1071-7. doi: 10.1213/ANE.0b013e3182691898. Epub 2012 Sep 13.</citation>
    <PMID>22984155</PMID>
  </reference>
  <verification_date>February 2008</verification_date>
  <study_first_submitted>November 20, 2006</study_first_submitted>
  <study_first_submitted_qc>November 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Staccato Fentanyl, Pharmacokinetics, Pharmacodynamics, inhaled fentanyl</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breakthrough Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

